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Abstract
Purpose of review—The Kallikrein-kinin system (KKS) constitutes a complex multi-enzyme
cascade that produces several bioactive kinin peptides and their derivatives including bradykinin.
In addition to the classical notion of the KKS as a potent vasodilator and a mediator of
inflammatory responses, recent studies suggest a link between the KKS and oxidative stress. A
number of established mouse model with altered levels of KKS components opened the way to
evaluate precise functions of the KKS. Here we review recent findings on the role of the KKS in
cardiovascular diseases and chronic kidney diseases, and discuss potential benefits of KKS
activation in these diseases.
Recent findings—Deletion of both B1R and B2R in a diabetic mouse model exacerbates its
renal phenotypes, suggesting that the KKS exerts protective effects on diabetic nephropathy by
suppressing oxidative stress, presumably via nitric oxide (NO) and prostaglandins (PGs).
Summary—Accumulating evidence has highlighted the importance of the KKS as a protective
system against oxidative stress and organ damage in the heart and kidney. The activation of the
KKS by ACE inhibitors and vasopeptidase inhibitors is likely to be beneficial in senescence-
associated cardiovascular diseases and chronic kidney diseases.
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Introduction
Kinins are generated by the proteolytic cleavage of kininogens by tissue or plasma
kallikreins and other serine proteases. Kinin peptides act via two types of kinin receptors:
the bradykinin B1 receptor (B1R/Bdkrb1) and the bradykinin B2 receptor (B2R/Bdkrb2)
(Fig. 1). B2R is constitutively expressed in most tissues, whereas B1R is induced under
stress conditions including inflammation and diabetes. Both B1R and B2R are seven
transmembrane receptors coupled with G-proteins, stimulation of which elevates
intracellular Ca++ concentrations and the phospholipase A2 activity and leads to the release
of various mediators including nitric oxide (NO), prostaglandins (PGs), arachidonic acids
and other inflammatory agents [1–3].
Several mouse models and human epidemiological studies have suggested that KKS activity
modifies oxidative stress and disease progression in the heart and kidney. In this review we
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classify this evidence into three sections according to the modification step the KKS: kinin
levels, receptor activity, and mediator production.
Regulation of the kinin levels by angiotensin I-converting enzyme (ACE)
The estimated half-life of kinin peptides is remarkably short (less than 30 seconds in plasma
[4]). Active kinins are rapidly cleaved by several kinin peptidases, primarily by angiotensin
I-converting enzyme (ACE), which inactivates bradykinin, kallidin (humans), and kallidin-
like peptide (rodents) by removing two amino acids from the carboxyl termini of these
substrates [2]. ACE also cleaves angiotensin I into an active vasoconstrictor angiotensin II,
although it has higher affinity for kinins than that for angiotensin I [5]. Modest changes in
ACE levels affect kinin levels more than angiotensin II levels, as supported by computer
simulations demonstrating that altered ACE levels have virtually no effect on the levels of
products, while they have marked effects on its substrates [6].
The systemic effects of quantitatively varied ACE activities were examined by utilizing
genetically engineered mice that carry different copy numbers of the ACE gene. The one-
copy mice showed 62% of plasma ACE activities of the wild-type (two-copy) mice, and the
three copy mice had 144% of normal [7]. A genetic decrease in ACE activity reduced
myocardial infarct size after ischemia/reperfusion injury, and the effect was completely
suppressed by pretreatment with a selective B2R antagonist [8]. In the streptozotocin (STZ)-
induced diabetic model, the onset of the proteinuria was accelerated in three-copy diabetic
mice [9]. These results indicate the protective effect of low ACE levels on oxidative stress-
associated diseases in the heart and kidney.
A naturally occurring polymorphism in human ACE gene, the I/D polymorphism, is
characterized by the insertion (I allele) or the non-insertion (D allele) of a 287-bp Alu
retrotransposon in intron 16. The polymorphism is associated with differences in the plasma
and tissue levels of ACE (I/I, 76%; I/D, 100%; D/D, 126% of average), and the D allele is
associated with higher levels of ACE and kallikrein [10, 11]. Many reports have indicated
that the D/D genotype may contribute to increased risks for cardiovascular and renal
diseases [12, 13].
Angiotensin-I converting enzyme (ACE) inhibitors are the most important agents that
augment KKS activity. While widely recognized as an inhibitor of renin-angiotensin-
aldosterone system (RAAS), their primary function is an upregulator of kinins rather than an
inhibitor of ACE. Indeed, the minimum effective dose of an ACE inhibitor perindopril for
increasing plasma bradykinin levels is much lower than that for reducing angiotensin II
levels [14]. This effect, partly explained in the preferential change in kinin levels more than
angiotensin levels, could also be mediated by higher affinity of bradykinin binding sites of
ACE than that of the angiotensin I binding sites by ACE inhibitor [15]. Moreover, it is
proposed that ACE inhibitors are the direct or indirect allosteric enhancers of B1R and B2R
[16].
The protective role of ACE inhibitors in cardiac and renal diseases has been well
documented [17]. Vasopeptidase inhibitors, which simultaneously inhibit ACE and
neprilysin (NEP), a circulating enzyme that degrades vasoactive peptides including
natriuretic peptides and kinins, also prevent diabetes and improve diabetic nephropathy in
rat models [18, 19]. The beneficial effects of ACE inhibitors and vasopeptidase inhibitors
are attenuated by a B2R antagonist in diabetic model animals, indicating that the protective
effects of ACE inhibitors are mediated by B2R signaling [19–21].
In addition to the ACE inhibitors, angiotensin receptor blockers (ARBs) are widely used
drugs proven to be reno- and cardio-protective. Although ARBs are considered to modulate
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RAAS, several studies demonstrated that the cardio-protective effect of an ARB losartan is
reduced by a selective B2R inhibitor, indicating that some effects of ARBs are mediated
through B2R activation [22]. The mechanism remains to be elucidated, however, Bonde et
al. recently proposed that losartan directly binds to and activate the B2R [23].
ACE inhibitors might be most effective in diabetic patients with the D allele of ACE gene,
however, clinical studies have given conflicting results [13]. Further studies on more
homogenous group are needed to assess the therapeutic effects of ACE inhibitors in patients
with different ACE genotypes.
Modulation of bradykinin receptor activity
Recent studies suggest the protective role of B2R in oxidative stress-mediated disorders of
the heart and kidney [20, 21, 24]. We have previously shown that the lack of B2R worsens
diabetic complications and accelerates premature aging in Akita (Ins2Akita/+) diabetic mice
[24]. The Akita mice lacking B2R develop senescence-associated phenotypes including
alopecia, skin atrophy, kyphosis, osteoporosis, and testicular atrophy. On the other hand,
another group reported that the lack of B2R protects against the development of STZ-
induced diabetic nephropathy [25]. The opposite results could possibly be caused by
differences in strain and age of the mice and in the method of induction of diabetes.
Whether B1R is beneficial or detrimental in the heart or kidney remains unclear. Although
lack of the B1R does not affect cardiac remodeling after myocardial infarction, blockade of
B2R worsened cardiac remodeling and dysfunction in B1R knockout mice but not in the
wild type mice [26]. In contrast, B1R knockout mice were protected against cardiac and
renal injury [27, 28]. A recent study also shows that activation of the B1R exacerbates
glomerulosclerosis [29]. However, as genetic disruptions of either receptor causes enhanced
expression of the remaining receptor, these results would not directly reflect the isolated
lack of either receptor.
To define the role of each receptor, we generated mice lacking both B1R and B2R [30*,
31**]. Susceptibility to renal ischemia/reperfusion injury was B1RB2R-null > B2R-null >
wild type, demonstrating that both B1R and B2R have protective roles in kidney [30*].
Furthermore, the lack of both B1R and B2R in the Akita diabetic mouse exacerbates the
pathological changes characteristic of diabetes, such as nephropathy, neuropathy, and
osteopathy (Fig. 2). Markedly elevated levels of plasma oxidative stress markers and
enhanced renal mitochondrial DNA damage suggest that the increased oxidative stress
contributes to the pathological changes in the B1RB2R-null/Akita mice [31**]. These
results clearly demonstrate that the KKS plays a protective role in the progression of
oxidative stress-related diseases, and suggest a novel therapeutic strategy in that the
modulation of the KKS could be beneficial for the treatment or prevention of these diseases.
In contrast to the deleterious effect of B1R and B2R deficiency in the kidney, no significant
changes in cardiac structure or function were observed in B1RB2R-null mice or B1RB2R-
null/Akita mice, although some parameters of cardiac dysfunction were decreased in
B1RB2R-null/Akita mice [32*, 33]. The different susceptibilities of the heart and kidney
imply the tissue-specific distributions and functions of each receptor.
In a human polymorphism in B2R gene (+9/−9 bp insertion/deletion), the insertion (+9)
allele is associated with decreased B2R gene transcription. The +9/+9 genotype is correlated
with greater cardiovascular risk including increased left ventricular hypertrophic responses
and higher systolic blood pressure, implying a harmful effect of the +9 allele [34]. In
contrast, the +9 allele is associated with a decreased progression of nephropathy in type 1
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and type 2 diabetic patients [35]. The association between +9/−9 polymorphism and risks of
the other oxidative stress-related diseases requires further clinical studies.
Intracellular mediator—NO and PGs
Reactive oxygen species (ROS), generated mainly by mitochondrial oxidative
phosphorylation, are considered to be the primary cause of aging through their damage to
DNA[36]. Dias et al. reported that activation of B1R increases the oxidative stress through
the activation of NADPH oxidase in the vasculature in a rat model [37]. In contrast, several
studies indicate that the B2R may contribute to reducing ROS. In STZ-treated
hyperglycemic rats, bradykinin reduces hydrogen peroxide and a biomarker of oxidative
stress. The protective effects of ACE inhibitors against oxidative stress are attenuated by a
B2R antagonist [38].
The KKS may contribute to the reduction of oxidative stress via NO and prostaglandin
(PGs) synthesis (Fig. 1). NO negatively regulates mitochondrial oxidative phosphorylation
by inhibiting cytochrome c oxidase, which is a key enzyme in the electron transport chain
[39]. Both the stimulation of B1R and B2R activates endothelial nitric oxide synthase
(eNOS/NOS3) leading to low and transient production of NO, and activates inducible NOS
(iNOS/NOS2), facilitating higher and prolonged release of NO [2, 3, 40]. Indeed, urinary
NO metabolites in B2R-null mice are lower than in WT [41], and the plasma NO
metabolites are lower in B1RB2R-null mice than in WT [30]. A polymorphism in the intron
4 of human eNOS gene is associated with an increased risk for diabetic nephropathy, and a
modest decrease in eNOS enhances the development of nephropathy in diabetic mice [42].
Bradykinin reduces mitochondrial superoxide generation in human vascular endothelial
cells, which is partly reversed by a NOS inhibitor [30]. Bradykinin also protects bovine
aorta endothelial cells from ROS-induced DNA damage and senescence through B2R-
mediated NO production [43]. Therefore, bradykinin-mediated NO production has the
potential of preventing ROS-induced pathogenesis.
Recent studies also suggest the protective effect of PGs against oxidative stress. PGI2
overexpression in renal tubular cells decreases aminoglycoside-induced production of ROS
and prevents apoptosis of these cells [44]. A PGI2 agonist cicaprost attenuates the
progression of diabetic renal injury in STZ-treated rats [45]. Therefore, the protective effect
of KKS may partially be mediated by NO and PGs.
Conclusions
ACE inhibitors have proven effective in long-term usage for the treatment of a constellation
of cardiac and renal diseases. Although the renin-angiotensin-aldosterone system has been
implicated in the pathogenesis, recent studies indicate that the benefits of the ACE inhibitors
are independent of the antihypertensive properties [46]. Meanwhile, accumulating evidence
suggests that potentiating the activity of KKS can protect against the progression of these
diseases, by suppressing oxidative stress presumably via production of NO and PGs. Thus,
the cardio- and reno-protective effect of ACE inhibitors could largely exerted by the
activation of the KKS.
Studies using B1RB2R-null mice indicate that non-selective stimulation of both receptors is
likely to have the higher therapeutic efficacies on diabetic nephropathy, while other studies
propose that the selective activation of the B2R and inhibition of B1R could be beneficial in
cardiovascular diseases. Further experimental and clinical investigations are warranted to
evaluate the long-term efficacy of the selective and non-selective KKS modulation.
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• Recent evidences suggest that the KKS has a protective role against oxidative
stress and organ damage in the heart and kidney.
• Phenotypes of B1R2R-null Akita mice, which lack both of the bradykinin
receptors in the diabetic background, indicate that both receptors protect against
the progression of diabetic nephropathy via the production of NO and PGs.
• Activation of the KKS by ACE inhibitors and vasopeptidase inhibitors is highly
beneficial in patients with diabetic complications.
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Figure 1. The KKS and suppression of oxidative stress
Kinins are generated from kininogens by kallikreins and are inactivated by ACE, NEP and
ECE. Binding of kinins to bradykinin receptors (B1R and B2R) leads to the reduction of
oxidative stress via NO and PGs. NEP, neprilysin; ECE, endothelin-converting enzyme.
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Figure 2. Pathological changes in the B1RB2R-null/Akita mice
PAS staining of renal glomeruli in 12-month-old male WT, B2R-null, B1RB2R-null, Akita,
B2R-null, and B1RB2R-null/Akita mice. Lack of bradykinin receptors enhances diabetic
glomerulosclerosis. Scale bar, 100 μm. Reproduced with permission from: [31**].
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